Samrat Pharmachem Limited (530125) Fair Value & Analysis
Other · IN · Market cap ₹355M
Fair value as of: Jul 4, 2026
From 9 valuation models · updated today
Share price +26.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹194.95 – ₹383.22 · fair‑value band ₹154.73 – ₹300.74 · the ₹261.35 price screens above the ₹227.73 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Samrat Pharmachem Limited (530125) currently trades at ₹261.35, while our model-based Fair Value estimate is ₹227.73 — implying the stock looks roughly 12.9% overvalued today. We read business quality at 50/100 (solid quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Samrat Pharmachem Limited generated revenue of ₹1.4B at a net margin of 2.3%. Revenue declined 0.7% year over year. Net debt stands at ₹48.2M. The stock trades on a trailing P/E of 7.0. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Samrat Pharmachem Limited manufactures and sells pharmaceutical chemicals in India. It offers iodine salts and bromines salts, as well as iodine derivatives for industries, such as pharmaceuticals, chemicals, food, fertilizers, salt, etc. The company also exports its products worldwide. Samrat Pharmachem Limited was founded in 1992 and is based in Mumbai, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Samrat Pharmachem Limited reported revenue of ₹2.9B in FY2026 versus ₹2.2B in FY2022, a compound +6.9%/yr. Reported net income was −₹33.1M in FY2026.
Is 530125 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Samrat Pharmachem Limited (530125) undervalued?
What is the fair value of 530125?
What is the quality score of 530125?
What is the revenue of Samrat Pharmachem Limited (530125)?
What is the net profit margin of 530125?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.